Becton, Dickinson and Company

Becton, Dickinson and Company

BDX

$198.60

Updated: 03/11/2026, 12:33:08

Market Cap
$54.10B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US

No historical data available

Company Profile

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

USD
NYSE
CEO: Thomas E. Polen Jr.
Employees: 72,000
https://www.bd.com
Asset Summaries
Latest generated summaries for BDX

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
BDX-10-k-fy2025.html2.9 MBtext/htmlENFiled 25/11/2025Period ended 30/09/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 36 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

N/A

FY — · Reported

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

BD Interventional organizational units and product lines
BD Medical organizational units and product lines
BD Life Sciences organizational units and product lines
Product/unit families by segment

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

BD company overview

Global medtech company (incorporated NJ 1906) selling medical supplies, devices, lab equipment and diagnostics worldwide

99%
Source evidence
“BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products”

Three reportable segments and announced reorganization to five

FY2025 segments: BD Medical, BD Life Sciences, BD Interventional; effective Oct 1, 2025 reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, Life Sciences

98%
Source evidence
“As of September 30, 2025, BD's operations consisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional”

Reportable segments FY2025

Medical, Life Sciences, Interventional (Life Sciences to be eliminated post Waters transaction)

96%
Source evidence
“Post-closing, the Life Sciences segment will be eliminated, and the Company will consist of the remaining four reportable segments.”

Life Sciences reorganization into two units (FY2025 Q1)

In FY2025 Q1, Integrated Diagnostic Solutions was split into Specimen Management and Diagnostic Solutions units

95%
Source evidence
“During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.”

Advanced Patient Monitoring revenue ramp (acquisition contribution)

Advanced Patient Monitoring revenues grew from $0 (FY2023) to $74M (FY2024) to $1,082M (FY2025)

90%
Source evidence
“Advanced Patient Monitoring658 424 1,082 47 27 74 — — —”

Customer categories by segment

Customers span hospitals, clinics, physicians' offices, retail pharmacies, government agencies, pharma/biotech, blood banks, ASCs and homecare patients

96%
Source evidence
“The primary customers served by BD Medical are hospitals and clinics; physicians' office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies”

Distribution model

Disposables distributed via acute/non-acute/lab/drug wholesaler distributors in the US; capital equipment mostly sold direct

95%
Source evidence
“In the United States, BD uses acute care, non-acute care, laboratory and drug wholesaler distributors to broadly support our overall disposable product demand”

BD Interventional organizational units and product lines

BD Interventional units: Surgery, Peripheral Intervention, Urology and Critical Care

97%
Source evidence
“Percutaneous transluminal angioplasty ("PTA") balloon catheters, radio frequency ablation catheters, peripheral vascular stents”

BD Medical organizational units and product lines

BD Medical units: Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, Advanced Patient Monitoring

97%
Source evidence
“Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems and support services”

BD Life Sciences organizational units and product lines

BD Life Sciences units: Diagnostic Solutions, Biosciences, Specimen Management

97%
Source evidence
“Fluorescence-activated cell sorters and analyzers; antibodies and kits for performing cell analysis”

Product/unit families by segment

Medical: MDS, MMS, Pharmaceutical Systems, Advanced Patient Monitoring; Life Sciences: Specimen Management, Diagnostic Solutions, Biosciences; Interventional: Surgery, Peripheral Intervention, Urology and Critical Care

97%
Source evidence
“Medication Delivery Solutions$2,789 $1,787 $4,575”

FY2025 worldwide revenue and growth bridge

FY2025 revenue $21.840B, +8.2% vs prior year (volume +3.2%, APM acquisition +4.8%, pricing -0.3%, FX +0.1%, other +0.4%)

98%
Source evidence
“Worldwide revenues in 2025 of $21.840 billion increased 8.2% from the prior-year period”

Segment revenues FY2025 vs FY2024 vs FY2023

FY2025: Medical $11,456M (MDS $4,575M, MMS $3,474M, PS $2,324M, APM $1,082M); Life Sciences $5,167M; Interventional $5,217M; Total $21,840M

98%
Source evidence
“Total Company revenues from continuing operations$12,790 $9,049 $21,840”

Segment operating income and margins FY2025

FY2025 segment operating income: Medical $4,140M (36.1%), Life Sciences $1,641M (31.8%), Interventional $2,253M (43.2%); pre-tax income from continuing ops $1,881M

96%
Source evidence
“Segment Operating Income$4,140 $1,641 $2,253 $8,034”

Operations and dependencies

Foreign currency derivative sensitivity

10% USD appreciation: $(42)M (2025), $(143)M (2024); 10% USD depreciation: $68M (2025), $147M (2024) pre-tax earnings impact

95%
Source evidence
“10% appreciation in U.S. dollar$(42)$(143)”

Manufacturing footprint outside the US

Manufacturing operations in 18 countries outside the US; international regions: EMEA, Greater Asia, Latin America, Canada

95%
Source evidence
“BD has manufacturing operations outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, Switzerland, and the United Kingdom”

Positioning and strategy

Acquisition of Edwards Lifesciences Critical Care (Advanced Patient Monitoring)

Acquired Edwards Critical Care for $3.914 billion on Sept 3, 2024; reported as Advanced Patient Monitoring within Medical segment

98%
Source evidence
“The fair value of consideration transferred in connection with the acquisition was $3.914 billion”

Proposed combination of Biosciences and Diagnostic Solutions with Waters

BD's Biosciences and Diagnostic Solutions business to combine with Waters, expected close ~Q1 CY2026; Life Sciences segment eliminated post-closing

97%
Source evidence
“The proposed combination of the Company’s Biosciences and Diagnostic Solutions business with Waters is expected to close around the end of the first quarter of calendar year 2026”

Advanced Patient Monitoring acquisition (2024)

2024 acquisition cash outflows attributable to acquisition of Advanced Patient Monitoring in Q4 2024

90%
Source evidence
“Cash outflows for acquisitions in 2024 was attributable to the acquisition of Advanced Patient Monitoring in the fourth quarter of 2024.”

Capital expenditures focused on manufacturing capacity

Capex of $760M (2025), $725M (2024), $874M (2023), primarily related to manufacturing capacity expansions

95%
Source evidence
“Capital expenditures of $760 million, $725 million and $874 million in 2025, 2024 and 2023, respectively, primarily related to manufacturing capacity expansions.”

Proposed Reverse Morris Trust combination of Biosciences and Diagnostic Solutions with Waters

RMT with Waters: BD shareholders ~39.2%, BD to receive ~$4B cash distribution, Waters to assume ~$4B incremental debt, expected close ~end of Q1 CY2026

98%
Source evidence
“BD expects to receive a cash distribution of approximately $4 billion prior to completion of the combination”

Completed divestitures: Surgical Instrumentation and Embecta spin-off

Sold Surgical Instrumentation platform Aug 2023 (~$268M pre-tax gain); spun off Diabetes Care as Embecta April 1, 2022

96%
Source evidence
“BD recognized a pre-tax gain on the sale of approximately $268 million”

Interventional segment Surgical Instrumentation platform divestiture (2023)

Divestiture of Interventional segment's Surgical Instrumentation platform generated $540 million cash inflows in 2023

92%
Source evidence
“Cash inflows relating to our divestiture of the Interventional segment's Surgical Instrumentation platform in 2023 were $540 million.”

R&D expense by segment FY2025

FY2025 R&D: $1,092M total; Medical $523M (4.6%), Life Sciences $315M (6.1%), Interventional $255M (4.9%)

95%
Source evidence
“Research and development expense523 315 255 1,092”

Strategic pillars: grow, simplify, empower

Strategy anchored in grow/simplify/empower: AI, robotics and smart-device innovation, portfolio rationalization, BD Excellence productivity, tuck-in M&A

93%
Source evidence
“Accelerating innovation in smart devices, robotics, analytics, and artificial intelligence in order to enable new care settings”

Risks, financing, and outlook

Total debt and weighted average cost

Total debt $19,181M (2025), $20,110M (2024), $15,879M (2023); weighted average cost 3.4% (2025)

98%
Source evidence
“Total debt (Millions of dollars)$19,181 $20,110 $15,879”

Senior unsecured revolving credit facility refinanced

New $2.750B senior unsecured revolving credit facility expiring September 2030, replaceable up to $3.250B; no borrowings outstanding at 9/30/2025

97%
Source evidence
“The credit facility provides borrowings of up to $2.750 billion, with separate sub-limits of $100 million and $236 million for letters of credit and swingline loans, respectively.”

Commercial paper programs

U.S. and multicurrency euro commercial paper programs, aggregate maximum unsecured borrowings of $2.750 billion

95%
Source evidence
“Our U.S. and multicurrency euro commercial paper programs provide for a maximum amount of unsecured borrowings under the two programs, in aggregate, of $2.750 billion.”

Key trends: China VoBP, research funding, vaccine demand, tariffs

Headwinds: China VoBP, cuts to governmental research funding, lower vaccine demand, healthcare budget pressure, and tariffs impacting FY2026 operating expense

96%
Source evidence
“we expect tariffs to adversely impact our operating expense for fiscal year 2026 and potentially beyond”

No material intersegment revenues

No material intersegment revenues; segment revenues are external

95%
Source evidence
“The Company has no material intersegment revenues.”

FDA Consent Decree on BD Alaris infusion pump business

CareFusion subsidiary operates under amended FDA Consent Decree for BD Alaris; 510(k) clearance received July 21, 2023; remediation substantially complete over next calendar year

95%
Source evidence
“Our CareFusion 303, Inc. subsidiary is operating under an amended Consent Decree that affects our BD Alaris™ infusion pump business in the United States.”

EU MDR and EU IVDR stricter device requirements

EU MDR/IVDR impose stricter clinical evidence, QMS and post-market surveillance requirements; MDR transition extended to 2027/2028

90%
Source evidence
“the application of the EU MDR has been extended until 2027 for certain devices considered higher-risk and to 2028 for other devices”

Two FDA warning letters for Dispensing and Specimen Management businesses

Currently operating under two FDA warning letters for the Dispensing and Specimen Management businesses

90%
Source evidence
“We are also currently operating under two warning letters issued by the FDA for our Dispensing and Specimen Management businesses.”

Tariffs expected to raise FY2026 operating expense

Tariffs expected to adversely impact FY2026 operating expense, primarily on imported products/components with limited mitigation

95%
Source evidence
“we expect tariffs to adversely impact our operating expense for fiscal year 2026 and potentially beyond, primarily relating to any products (or components) imported from countries across our global supply chain, for which there are limited mitigation opportunities.”

Supply chain shortages and disruptions

Experienced supply chain shortages/disruptions of materials and components and related price increases

90%
Source evidence
“We have also experienced, and may continue to experience, challenges in our global supply chain, including shortages in supply, or disruptions in production and shipments, of certain materials or components used in our products and related price increases.”

Customer consolidation and GPO purchasing pressure

Provider consolidation, GPOs and integrated delivery networks concentrate purchasing and pressure medical device prices

90%
Source evidence
“Group purchasing organizations and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward pricing pressure for medical device suppliers.”

Inflation persisted in FY2025 and expected to continue

Domestic and international markets experienced inflationary pressure in FY2025; inflation expected to persist

90%
Source evidence
“Both domestic and international markets experienced inflationary pressures in fiscal year 2025 and we expect inflation to persist in the future.”

Section 232 investigation into medical consumables/equipment imports

Commerce Department Section 232 investigation into PPE, medical consumables and equipment imports creates tariff policy uncertainty

90%
Source evidence
“the U.S. Department of Commerce recently initiated an investigation under Section 232 of the Trade Expansion Act of 1962, as amended, into (among other things) imports of personal protective equipment, medical consumables and medical equipment (including devices)”

Insurance may be inadequate for certain product liability claims

For certain product liability claims, BD does not maintain or has limited remaining insurance coverage

85%
Source evidence
“Also, for certain product liability claims or lawsuits, BD does not maintain or has limited remaining insurance coverage”

Geopolitical exposure: Ukraine, Middle East, Asia

Foreign operations exposed to changing political and geopolitical conditions in Ukraine, the Middle East and Asia

85%
Source evidence
“changing political, social, and geopolitical conditions, such as the continuation and/or escalation of the situation in Ukraine, the Middle East and Asia”

Anti-corruption (FCPA) compliance risk in international operations

International operations with foreign-government customers create FCPA/anti-bribery enforcement risk

85%
Source evidence
“our international operations, which often involve customer relationships with foreign governments, create the risk that there may be unauthorized payments or offers of payments made by employees, consultants, sales agents or distributors.”

Reimbursement and CMS Competitive Bidding Program pricing risk

Reimbursement changes and proposed CMS Competitive Bidding Program expansion could pressure device pricing in the U.S.

85%
Source evidence
“the Center for Medicaid Services ("CMS") has proposed the expansion of its Competitive Bidding Program ("CBP"). This proposed expansion would introduce a pricing model that could significantly influence the cost structure of some medical devices”

Shift of care from acute to non-acute settings

Care shifting from acute to non-acute settings pressures hospital finances and could reduce demand

85%
Source evidence
“the shift of care from acute to non-acute settings may also place financial pressure on hospitals and broader healthcare systems that could result in less demand for our products”

Material exposure graph

tariffs
Cost Driver

U.S. tariffs and foreign countermeasures expected to raise BD's operating expense in FY2026, primarily on imported products and components with limited mitigation options.

Relevance 90·Dependency 70·Confidence 90
Source evidence
“we expect tariffs to adversely impact our operating expense for fiscal year 2026 and potentially beyond, primarily relating to any products (or components) imported from countries across our global supply chain”
FDA amended Consent Decree (CareFusion/BD Alaris)
Regulatory Exposure

BD Alaris U.S. infusion pump business operates under an amended FDA Consent Decree; remediation/replacement of U.S. devices expected substantially complete over next calendar year, with cost/timing subject to customer readiness, supply continuity and FDA engagement.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“Our CareFusion 303, Inc. subsidiary is operating under an amended Consent Decree that affects our BD Alaris™ infusion pump business in the United States.”
global supply chain
Supplier Dependency

Shortages of materials and components used in BD products have caused supply and price pressure; management to date avoided significant disruption but no assurance it continues.

Relevance 85·Dependency 75·Confidence 85
Source evidence
“shortages in supply, or disruptions in production and shipments, of certain materials or components used in our products and related price increases”
Waters Corporation
Revenue Exposure

Pending RMT combination of BD's Biosciences and Diagnostic Solutions with Waters; BD to receive ~$4B cash distribution and shareholders to own ~39.2% of combined company.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“BD's shareholders are expected to own approximately 39.2% of the combined company”
Waters Corporation
Technology Dependency

Planned combination of BD's Biosciences and Diagnostic Solutions with Waters will restructure BD's portfolio, eliminating the Life Sciences segment and leaving four reportable segments.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“the Life Sciences segment will be eliminated, and the Company will consist of the remaining four reportable segments”
tariffs
Cost Driver

Tariffs on products/components imported across BD's global supply chain are expected to adversely impact FY2026 operating expense.

Relevance 82·Dependency 50·Confidence 92
Source evidence
“we expect tariffs to adversely impact our operating expense for fiscal year 2026 and potentially beyond”
inflation
Cost Driver

Inflation experienced in FY2025 and expected to persist affects demand, prices, supply chain and borrowing costs.

Relevance 80·Dependency 60·Confidence 85
Source evidence
“Both domestic and international markets experienced inflationary pressures in fiscal year 2025 and we expect inflation to persist in the future.”
China
Revenue Exposure

China market dynamics, specifically volume-based procurement (VoBP) programs and government compliance focus, have adversely impacted BD's results.

Relevance 80·Dependency 55·Confidence 90
Source evidence
“adverse impact to our results of operations due to market dynamics in China, such as volume-based procurement programs ("VoBP")”
Edwards Lifesciences
Revenue Exposure

The $3.914B Edwards Critical Care acquisition (Advanced Patient Monitoring) contributed 4.8 points of FY2025 revenue growth.

Relevance 78·Dependency 40·Confidence 95
Source evidence
“Acquisition of Advanced Patient Monitoring4.8 %”
Hospitals and healthcare systems
Demand Driver

Shift of care to non-acute settings pressures hospital finances, which could reduce demand for BD products.

Relevance 75·Dependency 70·Confidence 80
Source evidence
“the shift of care from acute to non-acute settings may also place financial pressure on hospitals and broader healthcare systems that could result in less demand for our products”
Group purchasing organizations
Competitive Exposure

GPOs and integrated delivery networks concentrate purchasing decisions, creating downward pricing pressure on BD's products.

Relevance 75·Dependency 65·Confidence 85
Source evidence
“Group purchasing organizations and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward pricing pressure for medical device suppliers.”
U.S. dollar
Currency Exposure

BD transacts across Europe, Greater Asia, Canada and Latin America; hedges substantially all transactional FX exposures with forward contracts and net investment hedges.

Relevance 75·Dependency 60·Confidence 95
Source evidence
“BD and its subsidiaries transact business in various foreign currencies throughout Europe, Greater Asia, Canada and Latin America.”
global logistics and supply chain
Supplier Dependency

BD has experienced temporary shortages of certain materials/components and depends on stable global transport flow; disruptions could adversely impact results.

Relevance 72·Dependency 55·Confidence 88
Source evidence
“The stable flow of global transport is critical to our operations and as such, events affecting the flow of logistics around the globe may adversely impact our supply chain”
EU Medical Device Regulation (EU) 2017/745
Regulatory Exposure

EU MDR/IVDR impose stricter clinical evidence, quality management and post-market surveillance requirements for marketing devices in the EU.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“each of which impose stricter requirements for the marketing and sale of medical devices, including in the area of clinical evidence, quality management systems and post-market surveillance”
Ethylene oxide litigation
Legal Exposure

BD is a defendant in product liability claims including ethylene oxide, hernia repair implants, pelvic organ prolapse products, vena cava filters and implantable ports; charges may exceed accruals.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“pending claims relating to ethylene oxide, our hernia repair implant products, surgical continence and pelvic organ prolapse products for women, vena cava filter products and implantable ports”
Advanced Patient Monitoring
Revenue Exposure

Acquisition of Advanced Patient Monitoring in Q4 FY2024 drove 2024 acquisition cash outflows and contributed to higher 2024 investing activity of $(5,514)M.

Relevance 70·Dependency 45·Confidence 90
Source evidence
“Cash outflows for acquisitions in 2024 was attributable to the acquisition of Advanced Patient Monitoring in the fourth quarter of 2024.”
government research funding
Demand Driver

Reductions or delays in governmental research funding have caused certain instrument customers to delay or forgo purchases.

Relevance 68·Dependency 45·Confidence 90
Source evidence
“reductions or delays in governmental research funding has caused customers for certain of our instruments to delay or forgo purchases of these products”
Foreign currencies
Currency Exposure

Given worldwide operations, BD faces translational foreign currency exposure on revenues and earnings; FX contributed +0.1% to FY2025 revenue growth.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“Each reporting period and given our worldwide operations, we face exposure to our results of operations from changes in foreign currencies”
SEC investigation
Legal Exposure

BD paid $175 million in fiscal 2025 relating to the SEC investigation, reducing operating cash flow.

Relevance 65·Dependency 30·Confidence 88
Source evidence
“our payment of $175 million relating to the SEC investigation as further discussed in Note 6”
vaccine-related products
Demand Driver

Lower demand for vaccines adversely impacted BD's results of operations.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“Lower demand for vaccines has also adversely impacted our results of operations”
interest rates
Cost Driver

BD balances fixed and floating rate instruments, using interest rate swaps; 10% rate change shifts derivative fair value by ~$11M and earnings/cash flows by ~$1M (2025).

Relevance 55·Dependency 40·Confidence 90
Source evidence
“We may enter into interest rate swaps to help maintain this balance and manage debt and interest-bearing investments in tandem”
Full company information
Latest profile, trading, valuation, and identifier data stored for BDX.
Share price
$198.60
Market cap
$54.10B
Exchange
NYSE
Currency
USD
CEO
Thomas E. Polen Jr.
Employees
72,000
IPO date
21/02/1973
Beta
0.279
Last dividend
$0.00
Day range
$197.23 – $199.92
52-week range
$127.59 – $200.47
1-day performance
0.36%
1-year performance
55.66%
Current drawdown (1Y)
-0.93%
CIK
0000010795
CUSIP
075887109
ISIN
US0758871091
Created
07/12/2025, 02:57:47
Last update
03/11/2026, 12:33:08

Track Becton, Dickinson and Company with an AI analyst

See which prediction-market events move BDX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BDX from your Railway `news_articles` table.